Cullinan Oncology, Inc.

Cullinan Oncology, Inc.verified

CGEM

Price:

$12.54

Market Cap:

$730.17M

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific...[Read more]

Industry

Biotechnology

IPO Date

2021-01-08

Stock Exchange

NASDAQ

Ticker

CGEM

The Enterprise Value as of November 2024 (TTM) for Cullinan Oncology, Inc. (CGEM) is 630.54M

According to Cullinan Oncology, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 630.54M. This represents a change of -7.10% compared to the average of 678.74M of the last 4 quarters.

Cullinan Oncology, Inc. (CGEM) Historical Enterprise Value (quarterly & annually)

How has CGEM Enterprise Value performed in the past?

The mean historical Enterprise Value of Cullinan Oncology, Inc. over the last ten years is 532.09M. The current 630.54M Enterprise Value has changed 11.75% with respect to the historical average. Over the past ten years (40 quarters), CGEM's Enterprise Value was at its highest in in the March 2021 quarter at 1.46B. The Enterprise Value was at its lowest in in the June 2023 quarter at -75962480.00.

Quarterly (TTM)
Annual

Average

532.09M

Median

318.37M

Minimum

-68448800.00

Maximum

1.24B

Cullinan Oncology, Inc. (CGEM) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Cullinan Oncology, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 301.24%

Maximum Annual Enterprise Value = 1.24B

Minimum Annual Increase = -579.35%

Minimum Annual Enterprise Value = -68448800.00

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2023328.11M-579.35%
2022-68448800.00-127.10%
2021252.56M-77.72%
20201.13B-8.48%
20191.24B301.24%

Cullinan Oncology, Inc. (CGEM) Average Enterprise Value

How has CGEM Enterprise Value performed in the past?

The current Enterprise Value of Cullinan Oncology, Inc. (CGEM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

170.74M

5-year avg

576.78M

10-year avg

532.09M

Cullinan Oncology, Inc. (CGEM) Enterprise Value vs. Peers

How is CGEM’s Enterprise Value compared to its peers?

Cullinan Oncology, Inc.’s Enterprise Value is greater than Bolt Biotherapeutics, Inc. (30.96M), less than Day One Biopharmaceuticals, Inc. (963.46M), greater than Lyra Therapeutics, Inc. (23.90M), greater than Autolus Therapeutics plc (177.55M), greater than Sana Biotechnology, Inc. (551.82M), greater than Olema Pharmaceuticals, Inc. (468.89M), greater than aTyr Pharma, Inc. (138.44M), greater than Zentalis Pharmaceuticals, Inc. (229.32M), greater than Century Therapeutics, Inc. (104.89M), less than Edgewise Therapeutics, Inc. (3.01B), greater than C4 Therapeutics, Inc. (307.45M), greater than Mineralys Therapeutics, Inc. (523.81M), greater than Talaris Therapeutics, Inc. (50.00M), greater than Adicet Bio, Inc. (-13122100.00), greater than Vor Biopharma Inc. (34.31M), greater than Lyell Immunopharma, Inc. (216.40M), greater than Monte Rosa Therapeutics, Inc. (439.72M), greater than Theseus Pharmaceuticals, Inc. (138.26M), less than Revolution Medicines, Inc. (9.43B),

Build a custom stock screener for Cullinan Oncology, Inc. (CGEM) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cullinan Oncology, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Cullinan Oncology, Inc. (CGEM) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Cullinan Oncology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Cullinan Oncology, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Cullinan Oncology, Inc. (CGEM)?

What is the 3-year average Enterprise Value for Cullinan Oncology, Inc. (CGEM)?

What is the 5-year average Enterprise Value for Cullinan Oncology, Inc. (CGEM)?

How does the current Enterprise Value for Cullinan Oncology, Inc. (CGEM) compare to its historical average?